Technical Analysis for GALT - Galectin Therapeutics Inc.

Grade Last Price % Change Price Change
grade C 3.88 8.99% 0.32
GALT closed up 8.99 percent on Wednesday, September 18, 2019, on 1.66 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical GALT trend table...

Date Alert Name Type % Chg
Crossed Above 50 DMA Bullish 0.00%
180 Bullish Setup Bullish Swing Setup 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Upper Bollinger Band Touch Strength 0.00%
50 DMA Resistance Bearish 8.99%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 8.99%
Fell Below 50 DMA Bearish 11.82%
Outside Day Range Expansion 11.82%
Crossed Above 50 DMA Bullish 7.48%
NR7 Range Contraction 7.48%

Older signals for GALT ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Galectin Therapeutics Inc., a development stage company, engages in the development of therapies for cancer and fibrotic disease. Its lead product candidates include GR-MD-02, a complex polysaccharide polymer for the treatment of liver fibrosis and fatty liver disease for which the company intends to initiate a Phase I clinical trial in patients with non-alcoholic steatohepatitis; and GM-CT-01, a linear polysaccharide polymer comprising mannose and galactose that is in a Phase I/II clinical trial in Europe as a combination therapy with a tumor vaccine in patients with advanced melanoma. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Cancer Tumor Hepatitis Therapies For Cancer Non Alcoholic Fatty Liver Disease Steatohepatitis Lectins Liver Fibrosis Europe Galectin Galectin 3
Is GALT a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 6.98
52 Week Low 2.94
Average Volume 260,760
200-Day Moving Average 4.2947
50-Day Moving Average 3.5645
20-Day Moving Average 3.4203
10-Day Moving Average 3.637
Average True Range 0.2427
ADX 18.56
+DI 26.6855
-DI 15.1084
Chandelier Exit (Long, 3 ATRs ) 3.2019
Chandelier Exit (Short, 3 ATRs ) 3.6681
Upper Bollinger Band 3.9292
Lower Bollinger Band 2.9114
Percent B (%b) 0.95
BandWidth 29.757624
MACD Line 0.0562
MACD Signal Line 0.0074
MACD Histogram 0.0488
Fundamentals Value
Market Cap 135.99 Million
Num Shares 35.1 Million
EPS -0.61
Price-to-Earnings (P/E) Ratio -6.36
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.39
Resistance 3 (R3) 4.35 4.14 4.31
Resistance 2 (R2) 4.14 4.01 4.16 4.28
Resistance 1 (R1) 4.01 3.93 4.08 4.05 4.25
Pivot Point 3.80 3.80 3.83 3.82 3.80
Support 1 (S1) 3.67 3.67 3.74 3.71 3.51
Support 2 (S2) 3.46 3.59 3.48 3.48
Support 3 (S3) 3.33 3.46 3.46
Support 4 (S4) 3.37